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Abstract
Background: Helminth infections may modulate immune responses to unrelated pathogens and allergens; these effects
may commence prenatally. We addressed the hypothesis that anthelminthic treatment in pregnancy and early childhood
would improve responses to immunisation and modulate disease incidence in early childhood with both beneficial and
detrimental effects.
Methods and Findings: A randomised, double-blind, placebo-controlled trial was conducted in Entebbe, Uganda
[ISRCTN32849447]. In three independent randomisations, 2507 pregnant women were allocated to receive single-dose
albendazole or placebo, and praziquantel or placebo; 2016 of their offspring were randomised to receive quarterly single-
dose albendazole or placebo from age 15 months to 5 years. Primary outcomes were post-immunisation recall responses to
BCG and tetanus antigens, and incidence of malaria, diarrhoea, and pneumonia; incidence of eczema was an important
secondary outcome. Analysis was by intention-to-treat. Of 2345 live births, 1622 (69%) children remained in follow-up at age
5 years. 68% of mothers at enrolment, and 11% of five-year-olds, had helminth infections. Maternal hookworm and
Schistosoma mansoni were effectively treated by albendazole and praziquantel, respectively; and childhood hookworm and
Ascaris by quarterly albendazole. Incidence rates of malaria, diarrhoea, pneumonia, and eczema were 34, 65, 10 and 5 per
100 py, respectively. Albendazole during pregnancy caused an increased rate of eczema in the children (HR 1.58 (95% CI
1.15–2.17), p = 0.005). Quarterly albendazole during childhood was associated with reduced incidence of clinical malaria (HR
0.85 (95% CI 0.73–0.98), p = 0.03). There were no consistent effects of the interventions on any other outcome.
Conclusions: Routine use of albendazole in pregnancy may not always be beneficial, even in tropical developing countries.
By contrast, regular albendazole treatment in preschool children may have an additional benefit for malaria control where
helminths and malaria are co-endemic. Given the low helminth prevalence in our children, the effect of albendazole on
malaria is likely to be direct.
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Introduction
It has been estimated that 2 billion people are infected with
schistosomes and soil-transmitted helminths (STH) [1] with up to
one third of the population of Sub-Saharan Africa affected by
STH infections. [2] Globally, malaria, diarrhoea and pneumonia
are the commonest causes of morbidity and mortality in
childhood, and together they account for nearly 50% of all
under-five deaths in Africa. [3] Tuberculosis incidence is estimated
at over 9 million new cases per year, with 1.8 million deaths, [4]
and the efficacy of Bacille Calmette Gue´rin (BCG) immunisation
against tuberculosis is poor in tropical latitudes. [5] The
geographic overlap between helminths and such important
infectious agents has led to the immunologically plausible
hypothesis that helminth infections influence the epidemiological
patterns of other diseases. [6]
Helminths induce potent type 2 and regulatory immune
responses, both of which may oppose the type 1 responses
required for protection against other pathogens, or by vaccines, [7]
thus increasing susceptibility to infectious diseases either directly,
or through diminution of vaccine effectiveness. Conversely, down-
regulation of unwanted inflammatory responses during chronic
helminth infection may have benefits. Contrasting effects of
helminths on susceptibility to malaria infection, and on the
damaging inflammatory sequelae, may explain in part the
conflicting results of previous studies on helminth-malaria
interactions, some of which suggest detrimental, and some
beneficial, effects. [8] Benefits may also include the prevention
of allergy and autoimmunity, [9] which are rare in tropical,
developing countries. [10] Prenatal exposure to helminths may be
particularly important: in utero exposure to maternal helminths has
long term implications for the child’s response to related worm
infections [11] but whether such immunological effects have a
measurable impact on efficacy of unrelated vaccines [12] or on
incidence of unrelated infectious diseases, and whether these
effects may be reversed by the administration of anthelminthics
during pregnancy and early childhood, is less clear. Helminth
infections in early childhood may also have important effects on
the responses generated as children undergo their initial exposures
to infections and allergens.
We established the Entebbe Mother and Baby Study to
investigate effects of helminths and their treatment during
pregnancy and early childhood on immune responses to vaccines
and on susceptibility to infectious and allergy-related diseases in
early childhood. [13] Findings in infancy showed little effect of
maternal helminths, or of their treatment during pregnancy, on
vaccine and infectious outcomes, [14,15] but significant adverse
effects of maternal anthelminthic treatment on infantile eczema.
[16] We have now investigated the effects of quarterly albendazole
versus placebo in preschool children, as well as the longer-term
effects to age 5 years of the intervention in pregnancy, on the recall
response to BCG and tetanus immunisation given in infancy, on
incidence of infectious diseases (malaria, diarrhoea and pneumo-
nia) and eczema, and on other outcomes for which anthelminthic
therapy has been proposed to be beneficial: anaemia, growth and
cognitive development. [17]
Materials and Methods
Study design and participants
As previously described, the study, based at Entebbe General
Hospital, Uganda, was a trial with three randomised, double-
blind, placebo-controlled interventions at two times, in a 262(62)
factorial design: women were randomised to albendazole versus
placebo and praziquantel versus placebo during pregnancy; their
children were randomised to quarterly albendazole versus placebo
from age 15 months to 5 years [ISRCTN32849447]. [13]
Written informed consent was obtained twice: from the mother
during pregnancy, and from the mother or caregiver when the
child reached age one year, or the first subsequent visit, for the
trial of treatment during childhood. The study was approved by
the Science and Ethics Committee of the Uganda Virus Research
Institute, the Uganda National Council for Science and Technol-
ogy and the ethics committee of the London School of Hygiene
and Tropical Medicine. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Randomisation and masking
Randomisation codes were generated by the trial statistician
using Stata version 7 (College Station, Texas, USA), with numbers
allocated in blocks of 100 and 80 to the mother and child
treatment groups, respectively; all three randomisations were
independent of each other.
Inclusion and exclusion criteria for the women, and intervention
and randomisation procedures during pregnancy have been
described in detail. [15] Briefly, healthy pregnant women from
the study area, and planning to deliver in Entebbe Hospital,
pregnant women were assigned in a 1:1:1:1 ratio to receive
simultaneously single-dose albendazole (400 mg) and praziquantel
(40 mg/kg), or albendazole and a praziquantel-matching placebo,
or an albendazole-matching placebo and praziquantel, or an
albendazole-matching placebo and a praziquantel-matching pla-
cebo (albendazole and matching placebo: GlaxoSmithKline,
Brentford, UK; praziquantel tablets, (Medochemie Ltd, Limassol,
Cyprus) were used to prepare identical praziquantel 300 mg and
placebo capsules (Almedica Europe Ltd, Deeside, UK)). The
intervention was given under direct observation, during the second
or third trimester of pregnancy.
When children made their first quarterly visits from age 15
months onwards, they were randomised in a 1:1 ratio to receive
quarterly albendazole or placebo. All children of participating
mothers were eligible for inclusion. From age 15 to 21 months,
children received syrups (5 ml) equivalent to 200 mg albendazole
or matching placebo, labelled according to the randomisation
code by the manufacturer. From age 2 to 5 years, children
received chewable tablets of albendazole (400 mg) or matching
placebo, packaged and sealed by an independent committee of
Medical Research Council staff in Entebbe, not otherwise involved
in the study, into consecutively numbered envelopes according to
the randomisation code. Trained study nurses allocated the
numbers sequentially and gave the quarterly intervention,
observing that it was taken correctly. All participants and study
staff were blinded to the drug allocation throughout the trial.
Procedures
Women provided a single stool sample prior to randomisation
and following delivery; all received anthelminthic treatment six
weeks after delivery. Their children were followed up for routine
immunisations, and then quarterly, to age 5 years. Children
received BCG and oral polio immunisations at birth, polio,
diphtheria, pertussis, tetanus, hepatitis B and Haemophilus influenzae
type B immunisations at 6, 10, and 14 weeks, and measles
immunisation at 9 months. At routine annual visits, blood and
stool samples were collected, and growth outcomes recorded.
Irrespective of their allocated intervention group, children found
to have helminth infections on examination of the annual stool
sample were treated as indicated for the species identified.
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Primary outcomes were immune response at age 5 years to
BCG and tetanus immunisation, and incidence of malaria,
diarrhoea, pneumonia, measles, and tuberculosis during child-
hood. Following evidence from our preliminary study of a possible
effect of maternal helminths and of albendazole treatment during
pregnancy on infantile eczema, [18] allergy-related disease events
were added as an important secondary outcome for the main trial.
[13] Other secondary outcomes were growth and anaemia
assessed at routine annual visits, and cognitive development. We
also considered asymptomatic Plasmodium falciparum parasitaemia
recorded at routine annual visits, as an unplanned exploratory
outcome.
Immunological assays were simplified compared to the original
protocol, for logistic and cost reasons. The recall response to
vaccines given during infancy was assessed at 5 years using
cytokine responses to crude culture filtrate proteins (cCFP) of
Mycobacterium tuberculosis, and antigen 85 (a major secreted protein
complex that exhibits cross-reactivity between many mycobacte-
rial species), and to tetanus toxoid, as indicators of response to
BCG and tetanus immunisation. We examined stimulated
interferon-c (type 1), interleukin-5 and interleukin-13 (type 2),
and interleukin-10 (regulatory) responses in a whole-blood assay,
as previously described [19]. Total serum anti-tetanus IgG was
measured by ELISA. [15]
Illness outcomes were detected prospectively when sick children
were brought to the clinic for treatment. Malaria was diagnosed as
fever ($37.5uC) with any parasitaemia (whether asexual forms or
gametocytes); diarrhoea was diagnosed based on the mother’s
definition; [20] pneumonia was defined as cough with difficulty in
breathing, and fast breathing (defined by age), with or without
abnormal breath sounds; [21] measles was defined by standard
clinical criteria confirmed by measurement of specific antibody;
[22] children with suspected tuberculosis were investigated as
clinically indicated; [23] eczema was defined as a recurrent itchy
rash with either wet, weeping skin or dry, scaly skin, and with a
typical distribution. One study doctor underwent specialised
training in the diagnosis of skin conditions at the National
Referral and Teaching hospital in Uganda, and trained other
doctors at the study clinic, to ensure accurate and consistent
definition of eczema. For development outcomes, children were
assessed at age 5 years at the study clinic for cognitive ability,
executive function and motor ability using 13 measures created or
adapted for the study (see Text S1 and Table S1). [24]
Haemoglobin was estimated by Coulter analyzer (Beckman
Coulter AC-T 5 diff CP; Beckman Coulter, Nyon, Switzerland).
Leishman stained thick blood films were examined for P. falciparum
ring forms or gametocytes. The modified Knott’s method was used
to examine for microfilariae. [25] Stools were examined for
helminth ova using the Kato-Katz method: [26] two slides were
prepared from each sample; slides were read within 30 minutes for
hookworm ova, and the following day for other species. Stools
were cultured for Strongyloides. [27] Urine examination for S.
haematobium was not conducted because it is rare in this setting.
[28] Quality control for haematology and malaria parasitology
was provided through the United Kingdom National External
Quality Assessment Schemes, and for Kato Katz analyses through
the Vector Control Programme of the Ministry of Health,
Uganda, with consistently good results. HIV status was deter-
mined for mothers at enrolment during pregnancy, and for
children aged 18 months or above, using a rapid antibody test
algorithm; for infants RNA and DNA polymerase chain reaction
methods were used. [15]
Serious adverse events were defined as any clinical event
considered by the clinician to be severe or life-threatening, or that
resulted in death. This included events requiring unexpected
hospitalisation or prolongation of hospitalisation, or resulting in
persistent or significant disability or incapacity, but not hospital-
isations expected in this setting for illnesses such as malaria. Pre-
specified serious adverse events include miscarriage, stillbirth,
neonatal death, major congenital abnormality, maternal death
during the puerperium, death of the child at any time and
anaphylaxis, severe acute bronchospasm or seizures within
24 hours of administration of the study drug.
Statistical analysis
Data were analysed after all children had reached age 5 years.
Data from routine annual visits were included if the child attended
within 1 month before and 2 months after their birthday. Results
for all twins and triplets were included. All analysis was by
intention-to-treat.
The cohort size of 2500 was calculated to give 80% power to
detect treatment effect sizes at p,0.05. For recall responses to
immunisation, allowing for anticipated loss to follow-up, samples
from 1046 children assessed at 5 years would detect differences in
cytokine responses of 0.14 log10 between maternal or childhood
intervention groups, assuming a standard deviation of 0.80 log10.
For illness events, a detrimental effect of anthelminthic
treatment was anticipated for malaria and eczema, and a
beneficial effect for other infections. For the childhood interven-
tion, estimated effect sizes that could be detected were rate ratios
of 1.07, 0.94, 0.81 and 1.30 for malaria, diarrhoea, pneumonia
and eczema, assuming rates in the placebo group of 80, 100, 10
and 5 per 100 person-years, respectively. The study had power to
detect slightly smaller long-term effects of the maternal interven-
tions, since the follow-up time (from birth to 5 years) was longer.
The incidence of both tuberculosis and measles was expected to be
low, therefore only very large differences in rates would be
detected.
To evaluate the effect of the childhood intervention on the
prevalence of each helminth, we combined data from all annual
visits, examining the overall effect of each treatment using
generalised estimating equation (GEE) logistic regression models
to calculate odds ratios (ORs) allowing for within-child correla-
tions.
Cytokine and antibody responses showed skewed distributions,
some with disproportionate numbers of zero values. Results were
transformed to log10(concentration+1) and analysed by linear
regression with bootstrapping to estimate bias-corrected acceler-
ated confidence intervals. [29] Regression coefficients were back-
transformed to give geometric mean ratios.
For long-term effects of maternal interventions on incidence of
diseases in childhood, time at risk began at birth. For effects of the
childhood intervention, sample size calculations assumed time at
risk from age 1 to 5 years. However, recognising that the
intervention actually commenced when the child took the first
intervention dose, the analysis plan was modified such that time at
risk began at the date of randomisation and receipt of the first dose
(age 15 months, or later if the child missed the 15-month visit). For
both analyses, time at risk was censored at loss to follow-up, death
or age 5 years. All children were included until censoring,
regardless of whether or not they had made a clinic visit for illness.
For each disease, we calculated incidence rates for all events.
Episodes within 14 days of an initial presentation with the disease
were considered to be part of the same episode and excluded from
the analysis; time at risk was adjusted accordingly. Hazard ratios
(HRs) for the effect of treatment on all-events disease incidence
were calculated using Cox regression with robust standard errors
to allow for within-child clustering. The prevalence of asymptom-
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atic malaria parasitaemia at each annual visit was compared
between treatment groups using logistic regression.
Sex-specific z-scores for weight-for-age, height-for-age and
weight-for-height at 5 years were derived from WHO growth
standard reference scales, using WHO Anthro version 3 for
children measured when aged less than 5 years and 1 month and
WHO AnthroPlus version 3 for children who were measured more
than 1 month (and less than 2 months) after their fifth birthday.
We examined the effects of the interventions on the continuous z-
scores and on haemoglobin at each annual visit using linear
regression. We also combined data from all annual visits,
examining the overall effect of each treatment using GEE linear
regression models to allow for within-child correlations. Effects of
the interventions on tests of motor and cognitive functioning at 5
years were examined using linear regression.
For the maternal interventions, two pre-specified subgroup
analyses were performed, examining effects of albendazole
treatment in children of mothers with hookworm infection, and
effects of praziquantel treatment in children of mothers with
schistosomiasis. Differences between subgroups were examined by
fitting interaction terms in regression models. For the childhood
intervention we conducted a post-hoc subgroup analysis of malaria
incidence by age group, fitting an interaction term to test for effect
modification. Interactions between the childhood intervention and
each maternal intervention were also examined by fitting
interaction terms in the regression models.
All p-values are two-sided with no adjustment made for multiple
comparisons. Data were analysed using Stata version 11, except
for developmental scores, for which SPSS version 16.0 was used.
Results
2507 women were enrolled between April 2003 and November
2005. Their offspring were followed from birth to age 5 years, the
planned end of the trial. There were 2345 live-born children of
whom 2016 were later randomised into the childhood intervention
trial, with 1622 remaining in follow-up at age 5 years (69%). The
trial profile for the maternal intervention up to the end of infancy
has been published previously. [15] The trial profile for the
childhood intervention is shown in Figure 1; follow-up was slightly
lower in the albendazole group compared to the placebo group
with numbers of children still under follow-up at 5 years of 792
and 830, respectively.
Baseline characteristics were comparable between the four
treatment groups in pregnancy (Table S2), [15] and between the
two treatment groups in childhood, with the exceptions that
maternal hookworm was slightly less prevalent, and eczema prior
to the childhood intervention slightly commoner, among children
allocated to quarterly albendazole than among those allocated to
placebo (Tables 1 and 2). Mothers of children who participated in
the childhood intervention were on average slightly older, less
likely to be primigravidae, and less likely to have asymptomatic P.
falciparum infection than mothers of children who did not
Figure 1. Flow of participants through the childhood trial.
doi:10.1371/journal.pone.0050325.g001
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Table 1. Baseline characteristics of mothers whose children were children enrolled in the trial of quarterly albendazole versus
placebo from age 15 months to five years.
Albendazole Placebo Albendazole
Number of mothers with children randomiseda 994 1002
Age in years, mean 6 SD 23.9565.38 23.7665.43
Education (4 mv)b
None 36 (4%) 33 (3%)
Primary 498 (50%) 509 (51%)
Secondary 381 (38%) 362 (36%)
Tertiary 79 (8%) 94 (9%)
Household socioeconomic status (41 mv)c
(low) 1 48 (5%) 67 (7%)
2 77 (8%) 88 (9%)
3 320 (33%) 289 (30%)
4 280 (29%) 281 (29%)
5 190 (19%) 203 (21%)
(high) 6 62 (6%) 50 (5%)
Gravidity
1 247 (25%) 265 (26%)
2–4 582 (59%) 571 (57%)
$5 165 (17%) 166 (17%)
Trimester at treatment (3 mv)
2 512 (52%) 506 (51%)
3 482 (48%) 493 (49%)
Maternal history of asthma (1 mv) 19 (2%) 22 (2%)
Helminth infections
Hookworm (7 mv) 459 (46%) 409 (41%)
S. mansoni (7 mv) 189 (19%) 177 (18%)
M. perstans (8 mv) 222 (22%) 201 (20%)
HIV positive 109 (11%) 94 (9%)
Malaria parasitaemia (36 mv) 104 (11%) 93 (9%)
Owns mosquito net (3 mv) 494 (50%) 519 (52%)
Intermittent preventive treatment for malaria during pregnancy (91 mv)
1 dose 230 (24%) 209 (22%)
2 doses 626 (66%) 654 (68%)
$3 doses 87(10%) 99 (10%)
Maternal tetanus immunisation during pregnancy
0 doses 220 (22%) 231 (23%)
1 dose 600 (60%) 592 (59%)
$2 doses 174 (18%) 179 (18%)
Maternal treatment
Albendazole+praziquantel 244 (24%) 256 (26%)
Albendazole placebo+praziquantel 247 (25%) 249 (25%)
Albendazole+praziquantel placebo 247 (25%) 257 (26%)
Double placebo 256 (26%) 240 (24%)
aThe number of mothers with children randomised is lower than the number of children randomised due to 20 sets of twins.
bmv: missing values.
cHousehold socioeconomic status was scored based on building materials of the home, number of rooms and items owned, ‘‘1’’ representing lowest and ‘‘6’’
representing highest status.
doi:10.1371/journal.pone.0050325.t001
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participate; children who participated were on average heavier at
birth, and less likely to be HIV positive or to have asymptomatic P.
falciparum at one year of age than those who did not. There was no
evidence of interaction between maternal and childhood treat-
ments for any outcome, therefore the effects of each treatment
were examined independently.
Following the childhood randomisation, adherence was slightly
lower in the albendazole group than in the placebo group,
reflecting the slightly lower follow-up in the albendazole group:
mean (SD) doses received (of a maximum of 16) was 11.8 (4.5) for
placebo versus 11.4 (4.1) for albendazole, p= 0.08; 22% versus
19% of participants received all 16 doses, respectively (p = 0.05).
Table 2. Characteristics of children enrolled in the trial of quarterly albendazole versus placebo from age 15 months to five years,
at the time of randomisation.
Albendazole placebo Albendazole
Number of children randomiseda 1006 1010
Age at randomisation in years, mean 6 SD 1.5260.54 1.5260.50
Male 531 (53%) 510 (51%)
Birthweight (362 mvb), mean 6 SD 3.1960.48 3.1660.50
HIV status
Unexposed 894 (89%) 914 (90%)
Exposed, uninfected 88 (9%) 79 (8%)
Exposed, infected 18 (2%) 13 (1%)
Exposed, unknown 6 (0.6%) 4 (0.4%)
P.falciparum at first annual visit (394 mv) 41 (5%) 51 (6%)
Any worm infection at first annual visit (536 mv) 19 (3%) 22 (3%)
Received deworming elsewhere during infancy (356 mv) 132 (16%) 161 (20%)
Number of clinic visits for illness before randomisation, mean 6 SD 6.5963.51 6.5263.44
Any clinic visit pre-randomisation for:
Malaria 361 (36%) 337 (33%)
Diarrhoea 747 (74%) 765 (76%)
Pneumonia 193 (19%) 184 (18%)
` Eczema 68 (7%) 98 (10%)
aThe number of mothers with children randomised is lower than the number of children randomised due to 20 sets of twins;
bmv: missing values;
doi:10.1371/journal.pone.0050325.t002
Table 3. The prevalence of helminth infection at each routine annual visit, by childhood treatment group.
Age
Helminth Childhood Treatment 2 years (n=1428)1 3 years (n=1429)1 4 years (n=1366)1 5 years (n=1319)1
Trichuris trichiura Placebo 10 (1.4%) 32 (4.4%) 40 (5.8%) 39 (5.8%)
Albendazole 16 (2.3%) 31 (4.4%) 35 (5.2%) 34 (5.3%)
Ascaris lumbricoides Placebo 14 (1.9%) 19 (2.6%) 11 (1.6%) 11 (1.6%)
Albendazole 7 (1.0%) 6 (0.9%) 6 (0.9%) 3 (0.5%)
Schistosoma mansoni Placebo 3 (0.4%) 5 (0.7%) 9 (1.3%) 20 (3.0%)
Albendazole 6 (0.9%) 7 (1.0%) 10 (1.5%) 10 (1.6%)
Hookworm Placebo 5 (0.7%) 7 (1.0%) 10 (1.4%) 2 (0.3%)
Albendazole 2 (0.3%) 1 (0.1%) 5 (0.7%) 3 (0.5%)
Hymenolepis nana Placebo 3 (0.4%) 7 (1.0%) 10 (1.5%) 7 (1.0%)
Albendazole 3 (0.4%) 7 (1.0%) 7 (1.0%) 6 (1.0%)
Mansonella perstans Placebo 2 (0.3%) 2 (0.3%) 2 (0.3%) 1 (0.1%)
Albendazole 1 (0.1%) 2 (0.3%) 3 (0.4%) 2 (0.3%)
Trichostrongylus Placebo 1 (0.1%) 1 (0.1%) 1 (0.1%) 0 (0%)
Albendazole 2 (0.3%) 0 (0%) 0 (0%) 0 (0%)
1For each annual visit, denominators are slightly lower than in Web Table 3 due to excluding children who were first randomised at that annual visit.
doi:10.1371/journal.pone.0050325.t003
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At each annual visit, between 20% and 30% of children were
reported to have received anthelminthic treatment elsewhere.
Over the four years of the childhood trial, 81% of those in the
placebo group and 83% of those in the albendazole group
reported receiving anthelminthic treatment elsewhere at least
once.
At enrolment, 68% of women were infected with at least one
helminth species, [15] but prevalence was low among children at
all annual visits: 3.6%. 5.6%. 8.9%. 11.0% and 10.5% at 1, 2, 3, 4
and 5 years, respectively.. At age 5 years, 5.5% of children were
infected with Trichuris trichiura, 2.3% with Schistosoma mansoni, 1.1%
with Ascaris lumbricoides, 1.0% with Hymenolepis nana, 0.5% with
hookworm, and 0.2% with Mansonella perstans (Table S3).
Combining data from all annual visits, the childhood intervention
was associated with a reduction in prevalence of A. lumbricoides and
hookworm (OR 0.41, 95% CI: 0.23–0.71, p= 0.001 and OR 0.47,
95% CI: 0.23–0.96, p = 0.04, respectively) but no other helminth
infection was affected (Table 3).
At age 5 years cytokine responses to mycobacterial antigens
were assessed among 1190 children who had received BCG
immunisation at Entebbe Hospital. Cytokine and antibody
responses to tetanus toxoid were assessed, respectively, among
1162 and 1129 children who had received all three doses of
tetanus immunisation. The proportion of children for whom
positive responses to cCFP, antigen 85 and tetanus toxoid were
detected varied by cytokine: for cCFP, 86%, 48%, 71% and 90%
of infants had positive responses to IFN-c, IL-5, IL-13 and IL-10,
respectively. Corresponding numbers for antigen 85 were 76%,
40%, 63% and 81%, respectively, and for tetanus toxoid the
figures were 39%, 39%, 60% and 52%, respectively. There was no
effect of anthelminthic treatment during pregnancy on these
responses, either overall, or in the pre-specified sub-group analyses
(data not shown). Quarterly treatment with albendazole was
associated with somewhat lower IFN- c, IL-5 and IL-13 responses
to cCFP (with strongest effects for IFN- c and IL-13), but no
similar effect was seen on responses to antigen 85 or to tetanus
toxoid, and there was no effect on anti-tetanus antibody levels
(Table 4).
From birth to 5 years, a total of 33,178 clinic visits for illness
were made; numbers of visits were similar across both maternal
and childhood treatment groups (data not shown). All-event
incidence rates for malaria, diarrhoea, pneumonia and eczema
were 34, 65, 10 and 5 per 100 person-years, respectively. Measles
and tuberculosis were very rare in the cohort with only 1 and 4
episodes observed, respectively, so it was not possible to evaluate
the impact of anthelminthic treatment on incidence of these
diseases. Neither maternal albendazole nor maternal praziquantel
had any effect on the incidence of malaria, diarrhoea or
pneumonia overall, or in the pre-specified sub-group analyses.
Maternal albendazole was associated with a higher rate of eczema
overall (HR 1.58 (95% CI 1.15, 2.17), p = 0.005) but maternal
praziquantel showed no such effect (HR 1.15 (95% CI 0.83, 1.58),
p = 0.40; Figure 2, Table 5). The effect of maternal albendazole
treatment was strong in infancy (HR 1.78 (95% CI 1.25, 2.55),
p = 0.002) and a diagnosis of eczema during infancy was a strong
predictor of further eczema in 1–5 year olds (HR 6.36 (95% CI
3.60, 11.22), p,0.001). After adjusting for a previous diagnosis of
eczema in infancy there was little evidence of an independent
effect of maternal albendazole in children aged 1 to 5 years (HR
1.20 (95% CI 0.75, 1.93), p = 0.44). The adverse effect of maternal
Table 4. The effect of quarterly albendazole during childhood on the recall response to mycobacterial and tetanus antigens, and
on anti-tetanus antibody levels, at age 5 years.
Intention-to-treat analysis





n= 616 n= 574
cCFP Interferon- c (pg/ml) 195 141 0.73 (0.56, 0.96)
IL-5 (pg/ml) 6.2 5.3 0.86 (0.69, 1.05)
IL-13 (pg/ml) 30 22 0.71 (0.55, 0.94)
IL-10 (pg/ml) 51 51 1.00 (0.82, 1.20)
n = 616 n= 574
Antigen 85 Interferon- c (pg/ml) 54 50 0.94 (0.72, 1.27)
IL-5 (pg/ml) 4.1 4.3 1.05 (0.84, 1.28)
IL-13 (pg/ml) 16 14 0.84 (0.64, 1.09)
IL-10 (pg/ml) 24 23 0.96 (0.80, 1.18)
n = 597 n= 565
Tetanus toxoid Interferon- c(pg/ml) 4.4 5.6 1.27 (0.97, 1.62)
IL-5 (pg/ml) 4.2 4.4 1.04 (0.85, 1.35)
IL-13 (pg/ml) 15 16 1.10 (0.85, 1.49)
IL-10 (pg/ml) 5.0 4.8 0.97 (0.81, 1.19)
n = 579 n= 550
Tetanus toxoid Total IgG (mIU/ml) 129 122 0.95 (0.76, 1.18)
cCFP: crude culture filtrate proteins of Mycobacterium tuberculosis.
ageometric mean of response concentration +1;
bbias-corrected accelerated confidence intervals computed by bootstrapping.
doi:10.1371/journal.pone.0050325.t004
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Figure 2. Effect of anthelminthic treatment during pregnancy on eczema incidence in the children. Kaplan-Meier survival estimates for
time to first (or only episode) of eczema (a) comparing children whose mothers received albendazole during pregnancy with those whose mothers
received albendazole-placebo (b) comparing children whose mothers received praziquantel during pregnancy with those whose mothers received
praziquantel-placebo. Numbers shown in the tables are number of events (in brackets) and number of children at risk.
doi:10.1371/journal.pone.0050325.g002
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albendazole appeared to be stronger among children of mothers
without hookworm than among children of mothers with
hookworm, but the interaction was not statistically significant
(p = 0.15). Maternal praziquantel showed no differential effect on
eczema according to maternal S. mansoni infection status (Table 6).
Childhood quarterly albendazole was associated with reduced
malaria incidence (HR 0.85 (95% CI 0.73, 0.98), p = 0.03;
Table 7), and a post-hoc subgroup analysis found that this effect
was strongest in the second year of life (interaction p= 0.002,
Figure 3).This trend was replicated in the prevalence of
asymptomatic P. falciparum parasitaemia at 2 years (Table 8).
There was no effect of childhood quarterly albendazole on
pneumonia, diarrhoea or eczema (Table 7).
There was no effect of maternal anthelminthic treatment
overall, or in pre-specified sub-group analyses, on childhood
haemoglobin levels or growth (data not shown). Additionally there
were no effects of childhood quarterly albendazole on these
parameters either when examining each annual visit separately
(Table 8), or when data were combined and analysed using GEE
regression models.
Table 5. The effect of anthelminthic treatment during pregnancy on incidence of malaria, diarrhoea, pneumonia and eczema
during early childhood (from birth to 5 years).
Albendazole Placebo Albendazole Praziquantel Placebo Praziquantel
Malaria Events (pyrs at risk6100) 1641 (47.67) 1640 (47.78) 1617 (48.21) 1664 (47.24)
Rate per 100 pyrs 34.43 34.32 33.54 35.22
Hazard ratio (95% CI) 1.00 (0.88–1.13) 1.04 (0.92–1.18)
P value 0.95 0.49
Diarrhoea Events (pyrs at risk6100) 3003 (47.14) 3127 (47.18) 3010 (47.68) 3120 (46.64)
Rate per 100 pyrs 63.71 66.28 63.13 66.90
Hazard ratio (95% CI) 1.04 (0.96–1.12) 1.05 (0.97–1.14)
P value 0.34 0.22
Pneumonia Events (pyrs at risk6100) 454 (48.11) 500 (48.17) 479 (48.64) 475(47.64)
Rate per 100 pyrs 9.44 10.38 9.85 9.97
Hazard ratio (95% CI) 1.10 (0.92–1.31) 1.00 (0.84–1.20)
P value 0.31 0.97
Eczema Events (pyrs at risk6100) 175 (48.21) 277 (48.26) 212 (48.74) 240 (47.73)
Rate per 100 pyrs 3.63 5.74 4.35 5.03
Hazard ratio (95% CI) 1.58 (1.15–2.17) 1.15 (0.83–1.58)
P value 0.005 0.40
There was no evidence of interaction between maternal albendazole and praziquantel treatments, therefore the effects of each treatment were examined
independently.
doi:10.1371/journal.pone.0050325.t005











N=1025 N=1311 N=421 N=1915
Malaria Hazard ratio for treatment
effect (95% CI)
1.09 (0.92,1.30) 0.92 (0.76–1.10) 1.09 (0.91,1.30) 0.98 (0.82,1.17)
P value for interaction 0.18 0.41
Diarrhoea Hazard ratio for treatment
effect (95% CI)
1.10 (0.98,1.24) 0.99 (0.89,1.10) 1.17 (0.96,1.43) 1.03 (0.95,1.12)
P value for interaction 0.17 0.26
Pneumonia Hazard ratio for treatment
effect (95% CI)
1.11 (0.85,1.46) 1.09 (0.85,1.38) 1.21 (0.81,1.80) 0.97 (0.79,1.19)
P value for interaction 0.90 0.33
Eczema Hazard ratio for treatment
effect (95% CI)
1.15 (0.72–1.83) 1.82 (1.19–2.79) 1.64 (0.87–3.07) 1.10 (0.76–1.58)
P value for interaction 0.15 0.28
doi:10.1371/journal.pone.0050325.t006
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At age 5 years, 870 participants were assessed on verbal and
nonverbal cognitive abilities, including executive function and
working memory, as well as motor abilities. Albendazole treatment
during pregnancy was associated with a marginally lower score on
one measure of executive function (the Wisconsin card-sorting test:
regression coefficient 20.54 (95% CI 21.07, 20.01; p = 0.05));
praziquantel treatment was associated with higher score on a gross
motor function, balancing on one leg (regression coefficient 1.58
(95%CI 0.04, 3.11; p= 0.04). No effects were observed in the pre-
specified subgroup analyses. There was no effect of childhood
quarterly albendazole on any score (Table S4).
Serious adverse events during pregnancy and infancy have been
described. [30,31] Twenty-nine deaths occurred during childhood.
There were no associations between maternal anthelminthic
treatments and mortality rate. One child developed severe malaria
within three days of receiving their first dose of albendazole at age
17 months, and died 6 weeks later following complications from
this illness event, but there was no suggestion of a consistent effect
of the childhood intervention on mortality: only 16 deaths
occurred after the childhood randomisation, 8 in the placebo
group and 8 in the albendazole group.
Discussion
In Entebbe, Uganda, where helminth prevalence was high
among pregnant women, we addressed the effects of treatment
with albendazole and praziquantel during the second and third
trimesters of pregnancy on outcomes from birth to 5 years. We
found no substantial effect of anthelminthic treatment during
pregnancy on the child’s response to immunogens, on infectious
disease incidence, or on anaemia, growth, motor or cognitive
development, to age 5 years. By contrast, treatment with
albendazole during pregnancy had an adverse effect on the
incidence of eczema in childhood. These longer-term results
accord with our findings in infancy [15,16]. Helminth infection
prevalence was unexpectedly low during early childhood, and this
limited our ability to assess the effects of the childhood
intervention against them. However, we found that quarterly
albendazole from age 15 months to 5 years reduced malaria
incidence, with strongest effect between age 15 months and 2
years.
Many studies on the effects of helminths and their treatment are
flawed due to bias and confounding, because of strong associations
between helminth infections and poverty, deprivation and poor
health care. A strength of this study was its randomised, placebo-
controlled design, which resulted in the balanced distribution of
many potential confounding factors between the treatment arms.
Helminth prevalence during pregnancy was high: the detection of
at least one species among 68% of women using a single stool
sample implies that almost all women were infected. [32,33] By
contrast, the low prevalence of helminth infection among children
was our chief limitation. For ethical reasons, effective treatment
was provided annually to children found to be helminth-infected;
therefore annual prevalence figures represent not cumulative
infection since birth, but cumulative incidence since the most
recent treatment. Although quarterly albendazole reduced infec-
tion rates with Ascaris and hookworm, the numbers infected were
so small that any consequence of this reduction would have had to
have been very strong to be detected in this study. Questions as to
the effects of helminth infection and their regular treatment in
preschool children therefore remain unanswered. A possible bias is
suggested by the somewhat higher uptake of the childhood
intervention by children receiving placebo, compared to those
receiving active drug. However, we had no evidence that either
staff or participants had inadvertently been unblinded to treatment
allocation. Mothers of children who participated in the childhood
intervention differed from mothers of children who did not. This is
unlikely to have biased our treatment effect estimates since
characteristics of participants were balanced between treatment
groups. However it may have reduced our power to detect effects
of anthelminthic treatment since the participants who were lost
tended to have higher prevalence of some helminths, and could
have some implications for generalisability since children who
participated in the childhood intervention were on average from
slightly more well-off families within the study setting. We
examined the effects of three interventions, each on multiple
outcomes; all analyses except for one exploratory outcome
(asymptomatic malaria parasitaemia) were pre-specified, however
the possibility that our positive findings are due to chance alone
cannot be discounted. Rather than formally adjusting for multiple
testing we interpret consistent results for related outcomes as
providing stronger evidence of a true treatment effect.
In keeping with results in infancy, we found no effect of
maternal anthelminthic treatment on recall responses to vaccine
antigens at age 5 years. Quarterly albendazole during childhood
was associated with reductions in type one and type two immune
Figure 3. Effect of quarterly albendazole from age 15 months to 5 years on infectious disease incidence in children. Kaplan-Meier
survival estimates for time to first (or only episode) of (a) malaria, (b) diarrhoea and (c) pneumonia during the intervention period, comparing children
who received quarterly albendazole with those who received placebo. Numbers shown in the tables are number of events (in brackets) and number
of children at risk.
doi:10.1371/journal.pone.0050325.g003
Table 7. The effect of quarterly albendazole during
childhood on incidence of malaria, diarrhoea, pneumonia, and
eczema (15 months to 5 years).
Albendazole
Placebo Albendazole
Malaria Events (pyrs at risk6100) 1006 (31.67) 845 (31.11)
Rate per 100 pyrs 31.77 27.16
Hazard ratio (95% CI) 0.85 (0.73–0.98)
P value 0.03
Diarrhoea Events (pyrs at risk6100) 1173 (31.59) 1147 (30.97)
Rate per 100 pyrs 37.13 37.04
Hazard ratio (95% CI) 0.99 (0.88–1.11)
P value 0.84
Pneumonia Events (pyrs at risk6100) 211 (31.97) 206 (31.35)
Rate per 100 pyrs 6.60 6.57
Hazard ratio (95% CI) 0.99 (0.76–1.28)
P value 0.92
Eczema Events (pyrs at risk6100) 77 (32.03) 107 (31.39)
Rate per 100 pyrs 2.40 3.41
Hazard ratio (95% CI) 1.25 (0.78–2.01)*
P value 0.36
*Hazard Ratio adjusted for eczema prior to randomisation and maternal
hookworm at enrolment.
doi:10.1371/journal.pone.0050325.t007
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responses to cCFP, but this was contrary to the predicted effect of
removing either worms or malaria and was not reflected by
responses to antigen 85, so these rather weak effects may have
arisen by chance.
We have previously reported that albendazole treatment during
pregnancy was associated with increased incidence of infantile
eczema, while praziquantel was associated with increased infantile
eczema among the offspring of mothers with schistosomiasis, and
that infantile eczema was associated with skin prick test positivity
to common allergens in this cohort. [16] Eczema incidence
declined, as expected, after infancy and we now show that the
incidence of newly diagnosed eczema after age 1 year was similar
between maternal treatment groups: thus the principal impact of
maternal albendazole was in infancy. The effect of praziquantel
treatment during pregnancy among infants of mothers with
schistosomiasis [16] waned with the longer follow-up period.
Eczema in infancy, however, remained a strong predictor of
subsequent episodes, and the long term impact of intrauterine
exposure on allergy-related outcomes such as asthma remains to
be determined. The effect of maternal albendazole was as strong
among children of women without hookworm (and indeed among
women without any helminth infection) as among children of
hookworm-infected women, implying a mechanism involving
effects on other organisms (such as malaria, as discussed below),
or a direct effect on the developing immune system. [16] The lack
of effect of our childhood intervention on eczema – unintentionally
tested largely in the absence of helminths – suggests that this
adverse effect of albendazole was confined to the prenatal period,
in keeping with studies suggesting that prenatal exposures are
critical in the programming of allergy-related disease. [34]
Given the low prevalence of helminths in childhood, we were
surprised by the effect of childhood albendazole on malaria
incidence. This seems unlikely to be a chance finding, because
illness events and asymptomatic parasitaemia showed the same
pattern. Direct inhibition of malaria by benzimidazoles, including
albendazole, has been demonstrated in vitro, [35] but effects in
vivo differ between animal models. [36] The effect was predom-
inantly seen between age 1 and 2 years, in the vulnerable period
Table 8. The effect of quarterly albendazole during childhood on asymptomatic malaria parasitaemia, haemoglobin and growth.
2 years 3 years 4 years 5 years
Repeated measures
analysis
Placebo Albendazole Placebo Albendazole Placebo Albendazole Placebo Albendazole
Effect
measure p-valuea
(n=745) (n =722) (n =759) (n =751) (n=743) (n =707) (n=726) (n=697) (95% CI)a
Asymptomatic malaria parasitaemia
Positive (%) 59 (8.1) 30 (4.3) 32 (4.3) 34 (4.7) 32 (4.5) 30 (4.4) 36 (5.1) 33 (4.9)
OR 0.51 1.09 0.99 0.95
(95% CI) (0.32–0.80) (0.66–1.78) (0.59–1.64) (0.59–1.55)
Haemoglobin









Difference 0.02 0.08 20.02 20.06 0.01 0.91
(95% CI) (20.11, 0.16) (20.33, 0.20) (20.17, 0.12) (20.19, 0.06) (20.08, 0.09)
Weight-for-age z-score







Difference 20.04 20.00 20.04 0.01 20.02 0.72
(95% CI) (20.15, 0.07) (20.11, 0.10) (20.14, 0.06) (20.11, 0.09) (20.10, 0.07)
Height-for-age z-score







Difference 0.09 0.06 0.03 20.06 0.03 0.58
(95% CI) (20.04, 0.23) (20.06, 0.18) (20.10, 0.15) (20.19, 0.07) (20.07,0.13)
Weight-for-height z-scorea







Difference 20.10 20.07 20.08 0.04 20.05 0.25
(95% CI) (20.24, 0.04) (20.19, 0.06) (20.20, 0.04) (20.10, 0.18) (20.14, 0.04)
Malaria parasitaemia results were missing for 39, 53, 52 and 38 children at ages 2, 3, 4 and 5 years, respectively; haemoglobin results were missing for 17, 28, 658b and 13
children at ages 2, 3, 4 and 5 years, respectively; weight-for-age z-scores were missing for 2, 0, 1 and 4 children at ages 2, 3, 4 and 5 years, respectively; height-for-age z-
scores were missing for 12, 2, 9 and 12 children at ages 2, 3, 4 and 5 years, respectively; weight-for-height z-scores were missing for 16, 4, 11 and 184c children at ages 2,
3, 4 and 5 years, respectively.
aThe effect of quarterly albendazole on asymptomatic malaria parasitaemia changed with time (interaction p= 0.02), therefore the overall effect of the intervention on
this outcome is not presented.
bHaemoglobin was not measured for four-year olds from 22nd January 2009 onwards due to budget constraints.
cWeight-for-height z-scores could not be calculated using WHO Anthro software for children who were aged .5 years and 1 month.
doi:10.1371/journal.pone.0050325.t008
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when maternal immunity has waned and individual immunity has
not yet been established: but this does not accord with the general
experience that antimalarial drugs have greater benefit among
individuals with good immunity than among those with poor
immunity. [37] Thus the potential contribution of regular
albendazole treatment to the control of malaria in young children
merits further investigation in trials designed with this as the
primary outcome. The observed effect of childhood albendazole
on malaria also has implications for the interpretation of other
studies addressing effects of benzimidazole anthelminthics on
growth, anaemia and mortality: outcomes for which malaria is
likely to have a more potent impact than helminths. For example,
Alderman and colleagues found benefits of albendazole for growth
when given to preschool children on child health days in malaria-
endemic regions of Uganda. [38] Similarly, the findings compli-
cate the interpretation of trials intended to assess the immunolog-
ical effects of removing helminths on susceptibility to malaria, such
as that recently reported from Nigeria, in which regular provision
of albendazole in preschool children reduced the prevalence of
Ascaris and attenuated the increase in malaria prevalence that
occurred over time. [39]
Our findings raise concerns regarding the policy of routine
‘‘deworming’’ with albendazole during pregnancy in developing
countries. Our study commenced in a setting of high helminth
prevalence, but low intensity. This picture has changed rapidly in
Entebbe, as in many towns across sub-Saharan Africa, with rapid
development and urbanisation over the last two decades: over
30% of Africans are now estimated to be ‘‘middle class’’. [40]
These demographic changes are accompanied by epidemiological
transition with non-communicable diseases, including allergy-
related conditions, [41] emerging as important health issues. While
routine anthelminthic treatment during pregnancy may be
acceptable in rural settings where hookworm infection is still
high, we believe it should be avoided in urban settings where
helminth infections are now low. Conversely, we found no
statistically significant adverse effect of albendazole in preschool
children, and large controlled trials suggest little impact of routine
anthelminthic treatment among school children on allergy-related
disease, [42,43] so it seems reasonable for on-going mass treatment
of worms to continue in these age groups, even as helminth
prevalence becomes marginal. Regular albendazole treatment in
preschool children may have an additional benefit for malaria
control, especially in areas where helminths and malaria are co-
endemic, and where IPTi is hampered because SP resistance is
high.
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